Trial Profile
A Retrospective Study Investigating the Safety and Initial Efficacy of Combined Nivolumab and Local-Regional (LR) Therapy in Advanced Hepatocellular Carcinoma (HCC) Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.